Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
US: How Insurers Are Finding Ways to Shift Costs to the Sick

Health insurance companies are no longer allowed to turn away patients because of their pre-existing conditions or charge them more because of those conditions. But some health policy experts say insurers may be doing so in a more subtle way: by forcing people with a variety of illnesses — including Parkinson’s disease, diabetes and epilepsy — to pay more for their drugs.

Published
18 September 2014
From
New York Times
Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.

Published
17 September 2014
From
Infojustice
Access to sofosbuvir in middle-income countries

Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.

Published
17 September 2014
From
I-MAK
Open Letter to President-elect Jean-Claude Juncker on move of medicinal products and health technologies to the portfolio of the Commissioner for internal market and industry

We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.

Published
17 September 2014
From
EATG
Gilead to raise price for new hepatitis C drug above $84000

The fixed-dose regimen version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

Published
15 September 2014
From
Reuters
New medicines in development give hope to patients with HIV/AIDS

America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Published
11 September 2014
From
Pharmaceutical Research and Manufacturers of America
Gilead close to sending $84,000 drug to poor countries

Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

Published
09 September 2014
From
Bloomberg
New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

Published
09 September 2014
From
HIVandhepatitis.com
Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs

An analysis of people who experienced treatment failure on their first-line HIV therapy with a viral load of over 400 copies/ml and who had taken either

Published
09 September 2014
By
Gus Cairns
Poor patients in India facing HIV/AIDS drug shortages

People with HIV in India are facing stoppages and shortfalls in their HIV treatment that have been blamed on supply bottlenecks, late payments to drugmakers and at least one large Indian manufacturer boycotting the process, complaining that the government was not paying it for its supply.

Published
05 September 2014
From
Reuters
← First12345...68Next →

Filter by country